CT 2820
Latest Information Update: 21 Sep 2007
At a glance
- Originator Celltech R&D
- Class Antiasthmatics
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 21 Sep 2007 Discontinued - Preclinical for Asthma in United Kingdom (unspecified route)
- 01 May 2001 Celltech Chiroscience Discovery is now called Celltech R&D
- 02 Feb 2000 Medeva has been merged into Celltech Chiroscience, which is now called Celltech Group